At present, seven trials have currently been reported for GLP-1 receptor agonists which include ELIXA (Evaluation of LIXisenatide in Acute coronary syndrome
GLP-1 patients regularly report a decreased pull toward substances, rather than increased willpower
Highly infiltrative growth patterns, cellular and molecular heterogeneity, a subpopulation of cells highly resistant to radiotherapy and chemotherapy, called glioma stem-like or glioma-initiating cells 3,4,5,6 , and a complex network of interactions between different tumor cell populations and the tumor microenvironment 7 have been held responsible for escape from current therapies
Effects of topically applied liquid N-acetylcysteine for the management of burning mouth syndrome
First-in-Human trials follow a cautious and progressive dose-escalation approach designed to support continuous safety evaluation throughout the study